9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
74 hedge funds and large institutions have $10.4M invested in 9 Meters Biopharma in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 26 closing their positions.
1,309% more call options, than puts
Call options by funds: $324K | Put options by funds: $23K
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
16% less funds holding
Funds holding: 88 → 74 (-14)
20% less capital invested
Capital invested by funds: $13M → $10.4M (-$2.6M)
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$466K |
| 2 |
Renaissance Technologies
New York
|
+$296K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$262K |
| 4 |
Two Sigma Investments
New York
|
+$210K |
| 5 |
RCM
Requisite Capital Management
Dallas,
Texas
|
+$74.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
Curi Wealth Management
Raleigh,
North Carolina
|
-$498K |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$469K |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$321K |
| 4 |
Millennium Management
New York
|
-$221K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$48K |
NMTR Hedge Fund Activity: Q3 2022 in Review
74 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q3 2022, worth a combined $10.4M — down 20% from $13M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of NMTR and 13 opened new positions — a net loss of 13 holders — while 16 trimmed existing stakes and 19 added.
The largest buyer was GSA Capital Partners, adding an estimated $466K. The largest seller was Curi Wealth Management, cutting an estimated $498K.
- 74 institutional investors held 9 Meters Biopharma (NMTR) as of Q3 2022, down from 88 in Q2 2022.
- Funds reported $10.4M of 9 Meters Biopharma stock for Q3 2022, down 20% quarter-over-quarter.
- 13 funds opened new 9 Meters Biopharma positions in Q3 2022 and 26 closed out, a net change of -13 holders.
- The largest 9 Meters Biopharma buyer in Q3 2022 was GSA Capital Partners, an estimated $466K added.
- The largest 9 Meters Biopharma seller in Q3 2022 was Curi Wealth Management, an estimated $498K sold.
Based on aggregated 13F filings for Q3 2022.